Based in Boston, MA, STRM.BIO (“storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.

Biotechnology

STRM.BIO

Jonathan Thon

Dawn Bell

Laura Goldberg

Sadettin Ozturk

Robert Hughes

Eric Crombez

David Raiser

The Leadership Team at STRM.BIO is responsible for guiding the strategic direction and operational execution of the company’s mission to revolutionize gene therapy through innovative extracellular vesicle technologies. Comprising key executives from operations, finance, technology, research, and medical expertise, the team collaborates to drive research initiatives, secure funding, oversee product development, and ensure compliance with industry regulations, all while fostering a culture of innovation and commitment to patient care. Together, they aim to establish STRM.BIO as a leader in biotherapeutics and make groundbreaking treatments accessible to patients with rare diseases.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at STRM.BIO

Research and Development